von Roemeling C, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, et al. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat Commun. 2020;11:1508 pubmed publisher

Wang P, Zhang Y, Su J, Yao K, Li S, Huang G, et al. Neutrophil depletion enhances the therapeutic effect of PD-1 antibody on glioma. Aging (Albany NY). 2020;12:15290-15301 pubmed publisher

Humeau J, Sauvat A, Cerrato G, Xie W, Loos F, Iannantuoni F, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med. 2020;12:e11622 pubmed publisher

Cheng W, Tsui Y, Ragusa S, Koelzer V, Mina M, Franco F, et al. Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nat Immunol. 2019;20:206-217 pubmed publisher

Wang W, Marinis J, Beal A, Savadkar S, Wu Y, Khan M, et al. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2018;34:757-774.e7 pubmed publisher

Sade Feldman M, Yizhak K, Bjorgaard S, Ray J, de Boer C, Jenkins R, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175:998-1013.e20 pubmed publisher

Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, et al. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest. 2018;128:2104-2115 pubmed publisher

Zhang Y, Kurupati R, Liu L, Zhou X, Zhang G, Hudaihed A, et al. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017;32:377-391.e9 pubmed publisher

Xie M, Koh B, Hollister K, Wu H, Sun J, Kaplan M, et al. Bcl6 promotes follicular helper T-cell differentiation and PD-1 expression in a Blimp1-independent manner in mice. Eur J Immunol. 2017;47:1136-1141 pubmed publisher

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495-499 pubmed publisher

Koyama S, Akbay E, Li Y, Herter Sprie G, Buczkowski K, Richards W, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501 pubmed publisher

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter Sprie G, et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016;76:999-1008 pubmed publisher

Cooper Z, Juneja V, Sage P, Frederick D, Piris A, Mitra D, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014;2:643-54 pubmed publisher

Park S, Namkoong H, Doh J, Choi J, Yang B, Park Y, et al. Negative role of inducible PD-1 on survival of activated dendritic cells. J Leukoc Biol. 2014;95:621-9 pubmed publisher

Duraiswamy J, Kaluza K, Freeman G, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591-603 pubmed publisher

Good Jacobson K, Song E, Anderson S, Sharpe A, Shlomchik M. CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. J Immunol. 2012;188:4217-25 pubmed publisher

Chen L, Sham C, Chan A, Francisco L, Wu Y, Mareninov S, et al. Role of the immune modulator programmed cell death-1 during development and apoptosis of mouse retinal ganglion cells. Invest Ophthalmol Vis Sci. 2009;50:4941-8 pubmed publisher

Menke J, Lucas J, Zeller G, Keir M, Huang X, Tsuboi N, et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol. 2007;179:7466-77 pubmed

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-7 pubmed

Liang S, Latchman Y, Buhlmann J, Tomczak M, Horwitz B, Freeman G, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33:2706-16 pubmed